Donald Menya, MD
Gynecologic Oncology · Tifton, GANPI 1194068601
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,000 of the $4,232 with a category attached, or 70.9%. Intuitive Surgical accounts for 71.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $3,016 and has fallen 96.4% since, to $107 in 2025.
Across 47 payments — averaging $90.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Astellas Pharma US Inc$352
- AbbVie$197
- Axonics, Inc.$129
- Aspira Women's Health Inc$123
- Hologic Sales And Service, LLC$113
- plus $288 from 8 others
What the payments were for
- Food & beverage$1,23229%
- Education$3,00071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $3,030 |
| Astellas Pharma US Inc | 12 | $352 |
| AbbVie | 10 | $197 |
| Axonics, Inc. | 3 | $129 |
| Aspira Women's Health Inc | 2 | $123 |
| Hologic Sales And Service, LLC | 7 | $113 |
| Coloplast | 1 | $71 |
| Baxter Healthcare | 2 | $60 |
| Pacira Pharmaceuticals Incorporated | 2 | $48 |
| Boston Scientific | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Coopersurgical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,000
- Veozah$122
- OVA1$112
How this compares
$4,232 in reported general payments places this provider in the 55th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 26 | $502 |
| Fluconazole | 39 | $342 |
| Terconazole | 12 | $311 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $162 |
| Metronidazole | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Tifton
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Margarett EllisonMoultrie$81K
- Vijaya GalicGainesville$35K
- Guilherme CantuariaAtlanta$13K
- Mitzie-Ann DavisFayetteville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.